$0.68
3.03% yesterday
Nasdaq, Sep 27, 09:34 pm CET
ISIN
US00091F1066
Symbol
ABVC
Sector
Industry

ABVC BioPharma Inc Stock price

$0.69
-0.02 3.21% 1M
-0.51 42.73% 6M
-0.47 40.75% YTD
-0.31 31.27% 1Y
-23.01 97.10% 3Y
-89.31 99.24% 5Y
-1,431.98 99.95% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.03 4.14%
ISIN
US00091F1066
Symbol
ABVC
Sector
Industry

Key metrics

Market capitalization $8.20m
Enterprise Value $9.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 68.93
P/S ratio (TTM) P/S ratio 58.57
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth -82.19%
Revenue (TTM) Revenue $140.00k
EBIT (operating result TTM) EBIT $-8.54m
Free Cash Flow (TTM) Free Cash Flow $-2.98m
Cash position $820.00k
EPS (TTM) EPS $-1.70
Short interest 1.16%
Show more

Is ABVC BioPharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ABVC BioPharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ABVC BioPharma Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast ABVC BioPharma Inc:

Hold
100%

Financial data from ABVC BioPharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.14 0.14
82% 82%
100%
- Direct Costs 0.20 0.20
53% 53%
143%
-0.06 -0.06
118% 118%
-43%
- Selling and Administrative Expenses 8.12 8.12
6% 6%
5,800%
- Research and Development Expense 0.32 0.32
88% 88%
229%
-8.51 -8.51
22% 22%
-6,079%
- Depreciation and Amortization 0.03 0.03
0% 0%
21%
EBIT (Operating Income) EBIT -8.54 -8.54
22% 22%
-6,098%
Net Profit -11 -11
10% 10%
-8,121%

In millions USD.

Don't miss a Thing! We will send you all news about ABVC BioPharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ABVC BioPharma Inc Stock News

Neutral
GlobeNewsWire
about one month ago
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) --   ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncol...
Neutral
GlobeNewsWire
5 months ago
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision...
Neutral
GlobeNewsWire
5 months ago
FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement w...
More ABVC BioPharma Inc News

Company Profile

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.

Head office United States
CEO Uttam Patil
Employees 19
Founded 1990
Website www.abvcpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today